Products with Anti-prostatic disease bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2164 | Silodosin |
| 1. Silodosin, a selective α-1a receptor antagonist, can increase passage of distal ureteral stones. 2. Silodosin can temporarily improve lower urinary tract symptoms (LUTS), but do not improve the bladder outlet obstruction index (BOOI) after implantation in the prostate, it is a useful option for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia . 3. Silodosin appears to suppress ejaculation in a relatively higher percent of trial participants, this suppression of ejaculation by silodosin suggested its potential for treating premature ejaculation. | |
| BCN2184 | Abiraterone Acotate |
| 1. Abiraterone acetate shows antitumour activity against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), it can significantly prolong overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel treatment. 2. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis. 3. Abiraterone acetate achieves sustained suppression of testosterone in both blood and bone marrow aspirate to less than picograms-per-milliliter levels. | |
| BCN2966 | Tomatine |
| Tomatine is a natural glycoalkaloid with anti-inflammatory, fungicidal, antimicrobial, and insecticidal properties. alpha-Tomatine activates phosphotyrosine kinase and monomeric G-protein signaling pathways leading to Ca(2+) elevation and ROS burst in F. oxysporum cells. | |
| BCN3127 | 6-Hydroxy-5,6-dehydrosugiol |
| 1. 6-Hydroxy-5,6-dehydrosugiol is a potent androgen receptor antagonist in prostate cancer cells, it has potential for use in chemoprevention and chemotherapy of prostate cancers. | |
| BCN3738 | Eriosemation |
| 1. Eriosemation significant androgen receptor (AR) inhibition activity, suggests that it could be a promising candidate for further evaluation for prostate cancer prevention or management. | |
